Telix Pharmaceuticals Announces Strategic Clinical Collaboration With Varian To Combine Theranostic Products With External Beam Radiation Therapy

Telix Pharmaceuticals Limited announced a strategic clinical collaboration with Varian, a Siemens Healthineers company and a global leader in radiation oncology, to develop new clinical applications that combine Telix’s theranostic products with external beam radiation therapy (EBRT). EBRT is a widely used treatment for many solid tumors and is typically administered by radiation oncologists, who play a critical role in managing cancer throughout a patient’s journey. By integrating therapeutic radiopharmaceuticals and precision diagnostics with EBRT, the collaboration aims to enhance the effectiveness of radiation oncology in treating cancer.

The initial focus of this collaboration is on PSMA-PET imaging for prostate cancer patients undergoing radiotherapy. Telix and Varian plan to explore how Gozellix® and Illuccix®, both kits for the preparation of gallium-68 (68Ga) gozetotide injection, can support patient selection, personalized treatment planning—especially in the context of Varian’s Ethos adaptive radiotherapy—and monitoring of treatment responses. The agreement will facilitate both company-sponsored and investigator-led clinical studies, allowing in-depth exploration of novel approaches.

Although the initial work is centered on PSMA imaging, the collaboration has been established as a broader framework for future co-development opportunities with wide clinical applicability. This includes other PET imaging candidates in Telix’s pipeline, such as TLX250-CDx (Zircaix®) and TLX101-CDx (Pixclara®), as well as potential future therapeutic radiopharmaceuticals. By combining Telix’s theranostic expertise with Varian’s EBRT technology, radiation oncologists are expected to be better equipped to deliver both definitive and palliative cancer treatments.

Dr. Arthur Kaindl, Head of Varian, said that working with Telix creates a pathway to integrate precision imaging and theranostics into the radiation therapy workflow, advancing personalized and optimized treatment decisions. He highlighted that combining Telix’s capabilities in molecular imaging and radiopharmaceuticals with Varian’s expertise in radiation therapy and treatment planning can enhance patient-focused cancer care.

Dr. Christian Behrenbruch, Group CEO and Managing Director of Telix, described the partnership as a transformative opportunity to bring precision imaging to the core of radiation oncology. He emphasized that integrating theranostics with EBRT has the potential to improve patient outcomes and that combining Telix’s innovation in molecular imaging with Varian’s leadership in cancer treatment technologies opens new possibilities in personalized cancer care.